Tata Motors Q4 FY26 Results: CV Business Revenue Rises 22%, PAT Jumps 70%
- By Kotak News Desk
- 14 May 2026 at 9:05 AM IST
- Market News
- 4m

Tata Motors’ commercial vehicle business reported Q4 FY26 revenue of ₹24,452 crore and PAT of around ₹2,400 crore.
Tata Motors delivered a strong quarter for its standalone commercial vehicle (CV) business in Q4 FY26. Revenue for the March quarter went up 22% year-on-year (YoY) to ₹24,452 crore, and EBITDA rose 35% YoY to ₹3,400 crore. EBITDA margin improved by 130 basis points to 13.9%.
Tata Motors CV share price closed at ₹384.25 on the National Stock Exchange, down by 0.72%.
Tata Motors Financial Performance
Profit before tax (before exceptional items) stood at ₹2,972 crore in Q4 FY26, up 58% YoY. Profit after tax for the quarter rose 70% YoY to around ₹2,400 crore.
For the full FY26, standalone revenue increased 11% YoY to ₹77,399 crore. EBITDA grew 22% YoY to ₹10,200 crore, while EBITDA margin improved to 13.2% from 12.0% a year ago. Profit before tax (before exceptional items) came in at ₹8,682 crore, up 46% YoY.
The company said full-year profit after tax stood at ₹3,400 crore, down 23% YoY due to exceptional items worth around ₹3,700 crore related to mark-to-market losses on listed investments in Tata Capital, costs linked to the new labour code and demerger-related expenses.
Tata Motors generated free cash flow of ₹9,186 crore during FY26, up ₹2,179 crore from the previous year. Net cash for the domestic business stood at ₹7,500 crore as of March 31, 2026. The company added that its disciplined capital allocation strategy helped it achieve a return on capital employed (ROCE) of 72% during FY26 compared with 61% in FY25.
On the consolidated front, Q4 FY26 revenue stood at ₹26,100 crore, up 19% YoY. EBITDA margin improved by 150 basis points to 13.1%, while profit after tax rose 35% YoY to ₹1,800 crore. The company stayed net cash-positive at ₹13,700 crore.
Commercial vehicle wholesales during the quarter stood at 132,000 units, up 25% YoY. Full-year wholesales increased 14% YoY to 428,000 units, with domestic and export volumes rising 12% and 54% respectively.
The board has recommended a final dividend of ₹4 per equity share for FY26, subject to approvals.
Also Read - GlaxoSmithKline Pharmaceuticals Q4 FY26 Results: PAT At ₹275 Crore, Board Recommends ₹57 Dividend
Source:
Company Press Release
This article is for informational purposes only and does not constitute financial advice. It is not produced by the desk of the Kotak Securities Research Team, nor is it a report published by the Kotak Securities Research Team. The information presented is compiled from several secondary sources available on the internet and may change over time. Investors should conduct their own research and consult with financial professionals before making any investment decisions. Read the full disclaimer here.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed SEBI prescribed limit. The securities are quoted as an example and not as a recommendation. SEBI Registration No-INZ000200137 Member Id NSE-08081; BSE-673; MSE-1024, MCX-56285, NCDEX-1262.

Kotak News Desk brings you latest updates, expert insights, and market-ready ideas - helping you stay informed and invest smarter.
Connect on: Linkedin
0 people liked this article.




